Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05593237 · ClinicalTrials.gov registry record · NA

Transcranial Magnetic Stimulation for Chronic Neuropathic Pain

A NA study of Spinal Cord Injuries and Pain, Postoperative, sponsored by University of California, San Francisco.

Active
Registry status
NA
Development phase
32
Enrollment target
1
Study location

NCT05593237 is a NA study of Spinal Cord Injuries and Pain, Postoperative that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 32 participants, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05593237, a NA study of Spinal Cord Injuries and Pain, Postoperative, is active but no longer recruiting, sponsored by University of California, San Francisco.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

Chronic neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory nervous system. It is highly prevalent, debilitating, and challenging to treat. Current available treatments have low efficacy, high side effect burden, and are prone to misuse and dependence. Emerging evidence suggests that the transition from acute to chronic neuropathic pain is associated with reorganization of central brain circuits involved in pain processing. Repetitive transcranial magnetic stimulation (rTMS) is a promising alternative treatment that uses focused magnetic pulses to non-invasively modulate brain activity, a strategy that can potentially circumvent the adverse effects of available treatments for pain. RTMS is FDA-approved for the treatment of major depressive disorder, obsessive-compulsive disorder, and migraine, and has been shown to reduce pain scores when applied to the contralateral motor cortex (M1). However, available studies of rTMS for chronic neuropathic pain typically show variable and often short-lived benefits, and many aspects of optimal treatment remain unknown, including ideal rTMS stimulation parameters, duration of treatment, and relationship to the underlying pain etiology. Here the investigators propose to evaluate the efficacy of high frequency rTMS to M1, the region with most evidence of benefit in chronic neuropathic pain, and to use functional magnetic resonance imaging (fMRI) to identify alternative rTMS targets for participants that do not respond to stimulation at M1. The central aim is to evaluate the pain relieving efficacy of multi-session high-frequency M1 TMS for pain. In secondary exploratory analyses, the investigator propose to investigate patient characteristic that are predictive of responsive to M1 rTMS and identify viable alternative stimulation targets in non-responders to M1 rTMS.

Interventions

  • DEVICE High Frequency rTMS
  • DEVICE Low Frequency rTMS

Study Locations (1)

California

  • UCSF Medical Center - San Francisco

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2022-04-25
Est. Completion 2026-12-30
Phase NA

What the Registry Record Tells You About NCT05593237

The ClinicalTrials.gov registry entry for NCT05593237 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (48% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 9 conditions, with Spinal Cord Injuries appearing as the primary indexed condition, and to 2 interventions - of which High Frequency rTMS is the first listed.

NCT05593237 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05593237 about?

NCT05593237 is a clinical study titled "Transcranial Magnetic Stimulation for Chronic Neuropathic Pain". Chronic neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory nervous system. It is highly prevalent, debilitating, and challenging to treat. Current available treatments have low efficacy, high side effect burden, and are prone to misuse and dependence. Emerging evi...

What is the current status of trial NCT05593237?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 32 participants. The study started on 2022-04-25. Estimated completion is 2026-12-30.

What conditions does trial NCT05593237 study?

This clinical trial studies the following conditions: Spinal Cord Injuries, Pain, Postoperative, Trigeminal Neuralgia, Complex Regional Pain Syndromes, Nerve Injury.

What interventions are being tested in trial NCT05593237?

The interventions under investigation include: High Frequency rTMS (DEVICE), Low Frequency rTMS (DEVICE).

Who is sponsoring clinical trial NCT05593237?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05593237 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Spinal Cord Injuries

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.